LEVERAGING DATA-DRIVEN INSIGHTS TO SUPPORT DEVELOPMENT OF TARGETED SUPPLEMENTAL BENEFITS UNDER NEWLY EXPANDED FLEXIBILITIES IN MEDICARE ADVANTAGE TO IMPROVE OUTCOMES IN HIGH-COST, HIGH-NEED BENEFICIARIES

Author(s)

Teigland C1, Pulungan Z2
1Avalere Health, Washington, DC, USA, 2Avalere Health, Bowie, MD, USA

OBJECTIVES : Compare characteristics, healthcare utilization, cost, and quality outcomes among dual eligible and non-dual eligible Medicare beneficiaries enrolled in Medicare Advantage (MA) plans.

METHODS : A retrospective cross-sectional analysis using a nationally representative sample of 1,813,937 MA enrollees from 103 contracts/512 benefit packages in 2015; 18% were full-benefit duals. Centers for Medicare and Medicaid Services (CMS) monthly membership reports were used to identify dual status and original reason for entitlement to Medicare.

RESULTS : A larger percent of full-dual beneficiaries were under age 65, while a similar proportion were 85 or older. Duals had higher prevalence of chronic conditions, including depression (2.3x), Alzheimer’s disease (2.4x), asthma (1.9x), heart failure (1.7x), stroke (1.5x), and diabetes (1.5x); 24% duals had Charlson Comorbidity Index (CCI) ≥5 versus 13% non-duals, and duals were also more likely to have complicating risk factors (e.g., obesity, severe mental illness, substance abuse). Based on top 10th percentile of annual spending, 17.1% duals were high-cost compared to 9.2% non-duals. Duals had higher utilization of emergency room visits (2.8x), hospitalizations (1.8x), and outpatient visits (1.5x). Costs were 1.7x higher; Part D drug costs 2.7x higher. Duals performed worse on all but one quality measure (QM), including 70% more likely to use high risk medications, 18% more likely to be hospitalized for potentially preventable complications, and less likely to receive preventive screenings or treatment for rheumatoid arthritis.

CONCLUSIONS : MA plans that serve a large number of duals face significant challenges. Duals are nearly twice as likely to be high-cost, and their lower performance on QMs impacts CMS Five Star Ratings and Bonus Payments. Starting in 2019, regulatory changes expand the scope of supplemental benefits MA plans can offer (e.g., non-health related). A better understanding of high-cost, high-need patients is essential to developing innovative benefit programs aimed at reducing costs and improving outcomes in this growing population.

Conference/Value in Health Info

2019-05, ISPOR 2019, New Orleans, LA, USA

Value in Health, Volume 22, Issue S1 (2019 May)

Code

PNS97

Topic

Clinical Outcomes, Economic Evaluation, Health Policy & Regulatory

Topic Subcategory

Clinical Outcomes Assessment, Cost/Cost of Illness/Resource Use Studies, Health Disparities & Equity, Reimbursement & Access Policy

Disease

No Specific Disease

Explore Related HEOR by Topic


Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×